Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.

Roland E Schmieder; Arnfried U Klingbeil; Erwin H Fleischmann; Roland Veelken; Christian Delles

doi:10.1681/ASN.2005020138

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.

Roland E Schmieder, Arnfried U Klingbeil, Erwin H Fleischmann, Roland Veelken, Christian Delles

Department of Internal Medicine IV, Division of Nephrology and Hypertensiology

Research output: Contribution to journal › Original Article › peer-review

110 Citations (Web of Science)

Original language	English
Pages (from-to)	3038-3045
Journal	JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume	16
Issue number	10
DOIs	https://doi.org/10.1681/ASN.2005020138
Publication status	Published - 2005

Keywords

CHRONIC KIDNEY-DISEASE
LEFT-VENTRICULAR HYPERTROPHY
TYPE-2 DIABETIC-PATIENTS
ESSENTIAL-HYPERTENSION
MEMBRANOUS GLOMERULOPATHY
CARDIOVASCULAR OUTCOMES
CAPTOPRIL THERAPY
IGA NEPHROPATHY
RENAL-FUNCTION
PROTEINURIA

Access to Document

10.1681/ASN.2005020138

Cite this

Schmieder, R. E., Klingbeil, A. U., Fleischmann, E. H., Veelken, R., & Delles, C. (2005). Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY , 16(10), 3038-3045. https://doi.org/10.1681/ASN.2005020138

Schmieder, Roland E ; Klingbeil, Arnfried U ; Fleischmann, Erwin H et al. / Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. In: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 2005 ; Vol. 16, No. 10. pp. 3038-3045.

@article{c38726cbf5de4a3d8f5a71b3fedbe310,

title = "Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.",

keywords = "CHRONIC KIDNEY-DISEASE, LEFT-VENTRICULAR HYPERTROPHY, TYPE-2 DIABETIC-PATIENTS, ESSENTIAL-HYPERTENSION, MEMBRANOUS GLOMERULOPATHY, CARDIOVASCULAR OUTCOMES, CAPTOPRIL THERAPY, IGA NEPHROPATHY, RENAL-FUNCTION, PROTEINURIA",

author = "Schmieder, {Roland E} and Klingbeil, {Arnfried U} and Fleischmann, {Erwin H} and Roland Veelken and Christian Delles",

year = "2005",

doi = "10.1681/ASN.2005020138",

language = "English",

volume = "16",

pages = "3038--3045",

journal = "JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY ",

issn = "1046-6673",

number = "10",

}

Schmieder, RE, Klingbeil, AU, Fleischmann, EH, Veelken, R & Delles, C 2005, 'Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.', JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY , vol. 16, no. 10, pp. 3038-3045. https://doi.org/10.1681/ASN.2005020138

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. / Schmieder, Roland E; Klingbeil, Arnfried U; Fleischmann, Erwin H et al.
In: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY , Vol. 16, No. 10, 2005, p. 3038-3045.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study.

AU - Schmieder, Roland E

AU - Klingbeil, Arnfried U

AU - Fleischmann, Erwin H

AU - Veelken, Roland

AU - Delles, Christian

PY - 2005

Y1 - 2005

KW - CHRONIC KIDNEY-DISEASE

KW - LEFT-VENTRICULAR HYPERTROPHY

KW - TYPE-2 DIABETIC-PATIENTS

KW - ESSENTIAL-HYPERTENSION

KW - MEMBRANOUS GLOMERULOPATHY

KW - CARDIOVASCULAR OUTCOMES

KW - CAPTOPRIL THERAPY

KW - IGA NEPHROPATHY

KW - RENAL-FUNCTION

KW - PROTEINURIA

U2 - 10.1681/ASN.2005020138

DO - 10.1681/ASN.2005020138

M3 - Original Article

C2 - 16120821

SN - 1046-6673

VL - 16

SP - 3038

EP - 3045

JO - JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

JF - JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IS - 10

ER -

Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY . 2005;16(10):3038-3045. doi: 10.1681/ASN.2005020138